Giovanni Paganelli

Giovanni Paganelli

Auto-generated profile, based on publicly available information

Giovanni Paganelli

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47121 Meldola, Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
UVUmberto Veronesi
Umberto Veronesi
GPGiovanni Paganelli
Giovanni Paganelli
GVGiuseppe Viale
Giuseppe Viale
ALAlberto Luini
Alberto Luini
SZStefano Zurrida
Stefano Zurrida
RGRoberto Gennari
Roberto Gennari
Although numerous studies have shown that the status of the sentinel node is an accurate predictor of the status of the axillary nodes in breast cancer, the efficacy and safety of sentinel-node biopsy require validation. From March 1998 to December 1999, we randomly assigned 516 patients with primary breast cancer in whom the tumor was less than or equal to 2 cm in diameter either to sentinel-node biopsy and total axillary dissection (the axillary-dissection group) or to sentinel-node biopsy followed by axillary dissection only if the sentinel node contained metastases (the sentinel-node group). The number of sentinel nodes found was the same in the two groups. A sentinel node was positive in 83 of the 257 patients in the axillary-dissection group (32.3 percent), and in 92 of the 259 patients in the sentinel-node group (35.5 percent). In the axillary-dissection group, the overall accuracy of the sentinel-node status was 96.9 percent, the sensitivity 91.2 percent, and the specificity 100 percent. There was less pain and better arm mobility in the patients who underwent sentinel-node biopsy only than in those who also underwent axillary dissection. There were 15 events associated with breast cancer in the axillary-dissection group and 10 such events in the sentinel-node group. Among the 167 patients who did not undergo axillary dissection, there were no cases of overt axillary metastasis during follow-up. Sentinel-node biopsy is a safe and accurate method of screening the axillary nodes for metastasis in women with a small breast cancer.

1 June 1997 in The Lancet
Verified
Journal Article
Closed access
UVUmberto Veronesi
Umberto Veronesi
GPGiovanni Paganelli
Giovanni Paganelli
VGViviana Galimberti
Viviana Galimberti
GVGiuseppe Viale
Giuseppe Viale
SZStefano Zurrida
Stefano Zurrida
PVPAOLO VERONESI
PAOLO VERONESI

17 February 1999 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
UVUmberto Veronesi
Umberto Veronesi
GPGiovanni Paganelli
Giovanni Paganelli
GVGiuseppe Viale
Giuseppe Viale
VGViviana Galimberti
Viviana Galimberti
ALAlberto Luini
Alberto Luini
DSDaniela Scarpa
Daniela Scarpa
BACKGROUND: Axillary lymph node dissection is an established component of the surgical treatment of breast cancer, and is an important procedure in cancer staging; however, it is associated with unpleasant side effects. We have investigated a radioactive tracer-guided procedure that facilitates identification, removal, and pathologic examination of the sentinel lymph node (i.e., the lymph node first receiving lymphatic fluid from the area of the breast containing the tumor) to predict the status of the axilla and to assess the safety of foregoing axillary dissection if the sentinel lymph node shows no involvement. METHODS: We injected 5-10 MBq of 99m Tc-labeled colloidal particles of human albumin peritumorally in 376 consecutive patients with breast cancer who were enrolled at the European Institute of Oncology during the period from March 1996 through March 1998. The sentinel lymph node in each case was visualized by lymphoscintigraphy, and its general location was marked on the overlying skin. During breast surgery, the sentinel lymph node was identified for removal by monitoring the acoustic signal from a hand-held gamma ray-detecting probe. Total axillary dissection was then carried out. The pathologic status of the sentinel lymph node was compared with that of the whole axilla. RESULTS: The sentinel lymph node was identified in 371 (98.7%) of the 376 patients and accurately predicted the state of the axilla in 359 (95.5%) of the patients, with 12 false-negative findings (6.7%; 95% confidence interval = 3.5%-11.4%) among a total of 180 patients with positive axillary lymph nodes. CONCLUSIONS: Sentinel lymph node biopsy using a gamma ray-detecting probe allows staging of the axilla with high accuracy in patients with primary breast cancer. A randomized trial is necessary to determine whether axillary dissection may be avoided in those patients with an uninvolved sentinel lymph node.

1 April 2010 in Annals of Surgery
Verified
Journal Article
Closed access
UVUmberto Veronesi
Umberto Veronesi
GVGiuseppe Viale
Giuseppe Viale
GPGiovanni Paganelli
Giovanni Paganelli
SZStefano Zurrida
Stefano Zurrida
ALAlberto Luini
Alberto Luini
DVDario Vezzoli
Dario Vezzoli
Sentinel node biopsy (SNB) is widely used to stage the axilla in breast cancer. We present 10-year follow-up of our single-institute trial designed to compare outcomes in patients who received no axillary dissection if the sentinel node was negative, with patients who received complete axillary dissection. From March 1998 to December 1999, 516 patients with primary breast cancer up to 2 cm in pathologic diameter were randomized either to SNB plus complete axillary dissection (AD arm) or to SNB with axillary dissection only if the sentinel node contained metastases (SN arm). The 2 arms were well-balanced for number of sentinel nodes found, proportion of positive sentinel nodes, and all other tumor and patient characteristics. About 8 patients in the AD arm had false-negative SNs on histologic analysis: a similar number (8, 95% CI: 3–15) of patients with axillary involvement was expected in SN arm patients who did not receive axillary dissection; but only 2 cases of overt axillary metastasis occurred. There were 23 breast cancer-related events in the SN arm and 26 in the AD arm (log-rank, P = 0.52), while overall survival was greater in the SN arm (log-rank, P = 0.15). Preservation of healthy lymph nodes may have beneficial consequences. Axillary dissection should not be performed in breast cancer patients without first examining the sentinel node.

2 October 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LBLisa Bodei
Lisa Bodei
MKMark Kidd
Mark Kidd
GPGiovanni Paganelli
Giovanni Paganelli
CGChiara M. Grana
Chiara M. Grana
IDIgnat Drozdov
Ignat Drozdov
IMIrvin M. Modlin
Irvin M. Modlin

1 December 2006 in The Lancet Oncology
Verified
Journal Article
Closed access
UVUmberto Veronesi
Umberto Veronesi
GPGiovanni Paganelli
Giovanni Paganelli
GVGiuseppe Viale
Giuseppe Viale
ALAlberto Luini
Alberto Luini
SZStefano Zurrida
Stefano Zurrida
JFJulia Rodríguez Fernández
Julia Rodríguez Fernández